Late relapse versus hepatitis c virus reinfection in patients with sustained virologic response after sofosbuvir-based therapies

Clinical Infectious Diseases

Volumn 64, Issue 1, 2017, Pages 44-52

  Sarrazin, Christoph ^a   Isakov, Vasily ^b   Svarovskaia, Evguenia S ^c   Hedskog, Charlotte ^c   Martin, Ross ^c   Chodavarapu, Krishna ^c   Brainard, Diana M ^c   Miller, Michael D ^c   Mo, Hongmei ^c   Molina, Jean Michel ^e   Sulkowski, Mark S ^d  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b FEDERAL RESEARCH CENTRE OF NUTRITION   (Russian Federation)

^c GILEAD SCIENCES   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Hepatitis c virus; Late recurrent viremia; Reinfection; Sustained virologic response; Viologic relapse

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; NONSTRUCTURAL PROTEIN 5B; RIBAVIRIN; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONSENSUS SEQUENCE; CONTROLLED STUDY; DRUG EFFICACY; GENETIC DISTANCE; GENETIC DRIFT; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MIXED INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PHYLOGENETIC TREE; PREVALENCE; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT INFECTION; REINFECTION; RELAPSE; RETREATMENT; SUSTAINED VIROLOGIC RESPONSE; VIREMIA; VIRUS LOAD; CHRONIC HEPATITIS C; CLASSIFICATION; COMBINATION DRUG THERAPY; DNA SEQUENCE; DRUG EFFECTS; FEMALE; GENETICS; GENOTYPE; HEPACIVIRUS; MALE; MICROBIOLOGY; PHYLOGENY; RECURRENT DISEASE; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; PHYLOGENY; PREVALENCE; RECURRENCE; RETREATMENT; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SOFOSBUVIR; TREATMENT OUTCOME; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS; VIREMIA;

EID: 85010645649     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw676     Document Type: Article

References (35)

1. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889-98.
2. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483-93.
3. Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 2015; 149:1454-61 e1.
4. Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: A proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis 2015; 15:1049-54.
5. Abergel A, Loustaud-Ratti V, Metivier S, et al. Ledipasvir/sofosbuvir for the treatment of patients with chronic genotype 4 or 5 HCV infection. In: International Liver Congress 2015, 50th Annual Meeting of the European Association for the Study of the Liver; 22-26 April 2015; Vienna, Austria.
6. Lam AM, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012; 56:3359-68.
7. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): An open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381:2100-7.
8. Rodriguez-Torres M, Lawitz E, Kowdley KV, et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial. J Hepatol 2013; 58:663-8.
9. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: A randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13:401-8.
10. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial. Lancet 2014; 383:515-23.
11. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370:1993-2001.
12. Wyles D, Pockros P, Morelli G, et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology 2015; 61:1793-7.
13. Osinusi A, Kohli A, Marti MM, et al. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: An open-label pilot study. Ann Intern Med 2014; 161:634-8.
14. Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013; 144:1450-5 e2.
15. Zeuzem S, Mensa FJ. Concordance between sustained virologic response week 12 (SVR12) and SVR24 in genotype 1 hepatitis C virus patients receiving interferonfree treatment in the SOUND-C2 study. Hepatology 2013; 58:1516.
16. Chen J, Florian J, Carter W, et al. Consideration of new endpoints for regulatory approval and dose selection of hepatitis C therapies [abstract LB-28]. In: 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 4-8 November 2011; San Francisco, CA.
17. Bernstein D, Mangia A, Brau N, et al. Concordance between SVR4, SVR12, and SVR24 in genotype 1 HCV-infected patients who received all oral fixed-dose combination ledipasvir/sofosbuvir with or without ribavirin in phase 3 clinical trials. In: The 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): The Liver Meeting; 7-11 November 2014; Boston, MA.
18. Lawitz E, Gane EJ, Lalezari J, et al. High concordance of SVR4, SVR12, and SVR24 in patients with HCV infection who have received treatment with sofosbuvir. In: 48th Annual Meeting of the European Association for the Study of the Liver; 24- 28 April 2013; Amsterdam, the Netherlands.
19. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
20. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-87.
21. Chulanov V, Zhdanov K, Kersey K, et al. Sofosbuvir plus ribavirin for the treatment of Russian patients with chronic HCV genotype 1 or 3 infection. In: The 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): The Liver Meeting; 7-11 November 2014; Boston, MA.
22. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312:353-61.
23. Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): A multicentre, openlabel, non-randomised, phase 3 study. Lancet 2015; 385:1098-106.
24. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88.
25. Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 2015; 61:56-65.
26. Svarovskaia ES, Dvory-Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis 2014; 59:1666-74.
27. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position- specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22:4673-80.
28. Zwickl DJ. Genetic algorithm approaches for the phylogenetic analysis of large biological sequence datasets under the maximum likelihood criterion [PhD dissertation]. University of Texas at Austin, 2006.
29. Anisimova M, Gascuel O. Approximate likelihood-ratio test for branches: A fast, accurate, and powerful alternative. Syst Biol 2006; 55:539-52.
30. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms and methods to estimate maximum-likelihood phylogenies: Assessing the performance of PhyML 3.0. Syst Biol 2010; 59:307-21.
31. Tamura K, Nei M. Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol Biol Evol 1993; 10:512-26.
32. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol 2013; 30:2725-9.
33. Esteban R, Nyberg L, Lalezari J, et al. Successful retreatment with sofosbuvircontaining regimens for HCV genotype 2 or 3 infected patients who failed prior sofosbuvir plus ribavirin therapy. In: 49th Annual Meeting of the European Association for the Study of the Liver London; 9-13 April 2014; United Kingdom.
34. Midgard H, Bjoro B, Maeland A, et al. Hepatitis C reinfection after sustained virological response. J Hepatol 2016; 64:1020-6.
35. van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009; 136:1609-17.